GC
AGIO icon

Grace Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Grace Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,300
Closed -$67K – 157
2021
Q1 		$67K Sell
1,300
-1,400
-52% -$69.3K 0.04% 200
2020
Q4 		$117K Buy
2,700
+1,500
+125% +$59.3K 0.07% 179
2020
Q3 		$42K Sell
1,200
-1,000
-45% -$43.8K 0.03% 209
2020
Q2 		$118K Hold
2,200
– – 0.1% 152
2020
Q1 		$78K Hold
2,200
– – 0.08% 134
2019
Q4 		$105K Sell
2,200
-3,900
-64% -$147K 0.09% 142
2019
Q3 		$198K Buy
6,100
+1,000
+20% +$41.4K 0.2% 109
2019
Q2 		$254K Sell
5,100
-1,100
-18% -$58.8K 0.12% 145
2019
Q1 		$418K Sell
6,200
-5,100
-45% -$297K 0.16% 137
2018
Q4 		$521K Buy
11,300
+1,800
+19% +$111K 0.24% 110
2018
Q3 		$731K Hold
9,500
– – 0.29% 81
2018
Q2 		$799K Buy
+9,500
New +$828K 0.31% 81

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Grace Capital's AGIO Position: Q2 2021 in Review

Grace Capital sold out of Agios Pharmaceuticals (AGIO) in Q2 2021, closing a stake of 1,300 shares — an estimated $67K sold.

Grace Capital first reported a position in AGIO in Q2 2018 and held it in 12 quarters. The position peaked at $799K in Q2 2018. 186 funds tracked by Wall St. Rank hold AGIO as of Q2 2021.

  • Grace Capital reported no remaining Agios Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Grace Capital sold 1,300 Agios Pharmaceuticals shares in Q2 2021, an estimated $67K.
  • Grace Capital first reported a position in Agios Pharmaceuticals in Q2 2018 and held it in 12 quarters.
  • Grace Capital's Agios Pharmaceuticals position peaked at $799K in Q2 2018.
  • 186 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2021.

Based on Grace Capital's 13F filing for Q2 2021, filed 11 Aug 2021.